Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin-resistant bladder tumor cell line

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 1803-1808

  Lee, Young Ju ^a   Lee, Sangchul ^a   Ho, Jin Nyoung ^a   Byun, Seok Soo ^a   Hong, Sung Kyu ^a   Lee, Sang Eun ^a   Lee, Eunsik ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Cisplatin; Drug resistance; Ginsenoside Rg3

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; CYCLIN B1; CYTOCHROME C; GINSENOSIDE RG 3; PROTEIN BAD; PROTEIN BCL 2; PROTEIN P21; ANTINEOPLASTIC AGENT; GINSENOSIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER RESISTANCE; CELL COUNTER; CELL COUNTING; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITOMETRY; DRUG MIXTURE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; WESTERN BLOTTING; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; PATHOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84907289379     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3452     Document Type: Article

References (26)

1. Ortmann CA and Mazhar D: Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Future Oncol 9: 1637-1651, 2013.
2. Choi YJ, Lee HJ, Kang DW, Han IH, Choi BK and Cho WH: Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species. Oncol Rep 30: 1362-1370, 2013.
3. Park HM, Kim SJ, Kim JS and Kang HS: Reactive oxygen species mediated ginsenoside Rg3-And Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways. Food Chem Toxicol 50: 2736-2741, 2012.
4. Jiang JW, Chen XM, Chen XH and Zheng SS: Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway. World J Gastroenterol 17: 3605-3613, 2011.
5. Zhang C, Liu L, Yu Y, Chen B, Tang C and Li X: Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Rep 5: 1295-1298, 2012.
6. Byun SS, Kim SW, Choi H, Lee C and Lee E: Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathionerelated enzyme activities. BJU Int 95: 1086-1090, 2005.
7. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
8. Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994.
9. Yoon CY, Park MJ, Lee JS, et al: The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. J Urol 185: 1102-1111, 2011.
10. Hong JH, Lee E, Hong J, Shin YJ and Ahn H: Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int 90: 113-117, 2002.
11. 2phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755, 1990.
12. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077, 2000.
13. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066-1073, 1992.
14. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1055, 1990.
15. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985.
16. Kim SM, Lee SY, Cho JS, et al: Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB. Eur J Pharmacol 631: 1-9, 2010.
17. Lee CK, Park KK, Chung AS and Chung WY: Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol 50: 2565-2574, 2012.
18. Entrez Gene: CCNB1 cyclin B1. Accessed January 15, 2014.
19. Chen JX, Peng HM, Pu SP and Guo YP: Inducement effect of ginsenoside Rg3 on apoptosis of human bladder transitional cell carcinoma cell line EJ. Zhongguo Zhong Yao Za Zhi 32: 1680-1684, 2007 (In Chinese).
20. Duggan BJ, Maxwell P, Kelly JD, et al: The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 166: 1098-1105, 2001.
21. Touloupidis S, Fatles G, Kalaitzis C, et al: The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 38: 231-236, 2006.
22. Glick SH, Howell LP and White RW: Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 155: 1754-1757, 1996.
23. Wu TT, Chen JH, Lee YH and Huang JK: The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 163: 758-760, 2000.
24. Uchida T, Minei S, Gao JP, Wang C, Satoh T and Baba S: Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol Rep 9: 253-259, 2002.
25. Bolenz C, Becker A, Trojan L, et al: Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. Urol Oncol 25: 476-482, 2007.
26. Le Bras M, Rouy I and Brenner C: The modulation of interorganelle cross-talk to control apoptosis. Med Chem 2: 1-12, 2006.